According to a filing with the U.S. Securities and Exchange Commission (), this new program is running under the code MTD217. Its focus is on developing “new therapeutic options for metastatic cancers with high unmet needs.”
Biodexa Pharmaceuticals notes that its first line of research will concern leptomeningeal disease. This is a complication that sees metastatic cancer cells invade the cerebrospinal fluid and central nervous system.
Midatech Pharma Plans for Trials
Midatech notes that it’s already working with several large academic centers. The goal is to advance preclinical studies to obtain proof of concept for leptomeningeal disease treatment. Doing so would pave the way for a clinical trial.
Dr. Dmitry Zamoryakhin, Chief Science Officer of Midatech, said the following about the news:
“We are very excited about accelerating this promising programme towards first-in-human studies. It capitalises on Midatech’s knowledge in direct intratumoral delivery of drugs, currently being explored in our clinical programme of MTX110 in recurrent glioblastoma. Furthermore, blockage of the OXPHOS pathway by MTD217 opens opportunities to demonstrate potential synergistic ef ects with checkpoint inhibitors in solid tumours as well as exploration of co-treatment with MTX110 in patients with aggressive brain tumours.”
BDRX stock is up 63.7% as of Tuesday morning.
There’s more stock market news worth looking into this morning!
Luckily, we’ve got all that news ready to go for traders! That includes the biggest pre-market stock movers this morning, as well as the latest on short squeeze stocks and more. You can find all that news at the links below!
More Tuesday Stock Market News
- Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
- Short Squeeze Stocks: BBBY, SI and 3 Other Stocks Ready to Squeeze
- AMC Stock Alert: AMC Announces Record Food Revenue
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
On the date of publication, William White did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.